Nodal metastasis in cervical cancer occurs in clearly delineated fields of immune suppression in the pelvic lymph catchment area

Oncotarget

Volumn 6, Issue 32, 2015, Pages 32484-32493

  Heeren, A Marijne ^a   de Boer, Eline ^a   Bleeker, Maaike C G ^a   Musters, René J P ^b   Buist, Marrije R ^c   Kenter, Gemma G ^a,c,d   de Gruijl, Tanja D ^a   Jordanova, Ekaterina S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Cervical cancer; Clinical Section; Metastatic niche; PD L1 myeloid cells; Tregs; Tumor draining lymph nodes

Indexed keywords

ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; HLA DR ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER;

ADULT; ARTICLE; BONE MARROW CELL; CD8+ T LYMPHOCYTE; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOXP3+ REGULATORY T LYMPHOCYTE; HLA DR+ - MYELOID CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHATIC DRAINAGE; MIDDLE AGED; PD L1+ MYELOID CELL; PELVIS LYMPH NODE; RADICAL HYSTERECTOMY; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UTERINE CERVIX CANCER; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; FLUORESCENT ANTIBODY TECHNIQUE; HYSTERECTOMY; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPH NODE; PATHOLOGY; PELVIS; PHENOTYPE; SECONDARY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; UTERINE CERVICAL NEOPLASMS;

ADULT; ANTIGENS, CD274; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FORKHEAD TRANSCRIPTION FACTORS; HLA-DR ANTIGENS; HUMANS; HYSTERECTOMY; IMMUNOPHENOTYPING; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; NEOPLASM STAGING; PELVIS; PHENOTYPE; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE; UTERINE CERVICAL NEOPLASMS;

EID: 84946094838     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5398     Document Type: Article

References (32)

1. Piersma SJ. Immunosuppressive tumor microenvironment in cervical cancer patients. Cancer Microenviron. 2011; 4:361-375.
2. Nakamura T, Shima T, Saeki A, Hidaka T, Nakashima A, Takikawa O, Saito S. Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci. 2007; 98:874-881.
3. Karim R, Jordanova ES, Piersma SJ, Kenter GG, Chen L, Boer JM, Melief CJ, van der Burg SH. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res. 2009; 15:6341-6347.
4. Munn DH, Mellor AL. The tumor-draining lymph node as an immune-privileged site. Immunol Rev. 2006; 213:146-158.
5. Mellor AL, Munn DH. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat Rev Immunol. 2008; 8:74-80.
6. Swartz MA, Lund AW. Lymphatic and interstitial flow in the tumour microenvironment: linking mechanobiology with immunity. Nat Rev Cancer. 2012; 12:210-219.
7. Heeren AM, Koster BD, Samuels S, Ferns DM, Chondronasiou D, Kenter GG, Jordanova ES, de Gruijl TD. High and Interrelated Rates of PD-L1+CD14+ Antigenpresenting Cells and Regulatory T cells mark the Microenvironment of Metastatic Lymph Nodes from Patients with Cervical Cancer. Cancer Immunol Res. 2015; 3:48-58.
8. van der Burg SH, Piersma SJ, de JA, van der Hulst JM, Kwappenberg KM, van den Hende M, Welters MJ, Van Rood JJ, Fleuren GJ, Melief CJ, Kenter GG, Offringa R. Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc Natl Acad Sci U S A. 2007; 104:12087-12092.
9. Battaglia A, Buzzonetti A, Baranello C, Ferrandina G, Martinelli E, Fanfani F, Scambia G, Fattorossi A. Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer. Cancer Immunol Immunother. 2009; 58:1363-1373.
10. Heeren AM, Kenter GG, Jordanova ES, de Gruijl TD. CD14+ macrophage-like cells as the linchpin of cervical cancer perpetrated immune suppression and early metastatic spread: a new therapeutic lead? Onco Immunology. 2015; 7:4.
11. clinicaltrials.gov2015.
12. Fransen MF, Arens R, Melief CJ. Local targets for immune therapy to cancer: tumor draining lymph nodes and tumor microenvironment. Int J Cancer. 2013; 132:1971-1976.
13. Fattorossi A, Battaglia A, Ferrandina G, Buzzonetti A, Legge F, Salutari V, Scambia G. Lymphocyte composition of tumor draining lymph nodes from cervical and endometrial cancer patients. Gynecol Oncol. 2004; 92:106-115.
14. Nagaraj S, Schrum AG, Cho HI, Celis E, Gabrilovich DI. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol. 2010; 184:3106-3116.
15. Umansky V, Sevko A. Tumor microenvironment and myeloid-derived suppressor cells. Cancer Microenviron. 2013; 6:169-177.
16. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012; 24:207-212.
17. Rose PG. Chemoradiotherapy for cervical cancer. Eur J Cancer. 2002; 38:270-278.
18. Benedetti PP, Basile S, Angioli R. Pelvic and aortic lymphadenectomy in cervical cancer: the standardization of surgical procedure and its clinical impact. Gynecol Oncol. 2009; 113:284-290.
19. Suprasert P, Srisomboon J, Charoenkwan K, Siriaree S, Cheewakriangkrai C, Kietpeerakool C, Phongnarisorn C, Sae-Teng J. Twelve years experience with radical hysterectomy and pelvic lymphadenectomy in early stage cervical cancer. J Obstet Gynaecol. 2010; 30:294-298.
20. Biewenga P, van d V, Mol BW, Stalpers LJ, Schilthuis MS, van der Steeg JW, Burger MP, Buist MR. Prognostic model for survival in patients with early stage cervical cancer. Cancer. 2011; 117:768-776.
21. Piersma SJ, Jordanova ES, van Poelgeest MI, Kwappenberg KM, van der Hulst JM, Drijfhout JW, Melief CJ, Kenter GG, Fleuren GJ, Offringa R, van der Burg SH. High number of intraepithelial CD8+ tumorinfiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 2007; 67:354-361.
22. Jordanova ES, Gorter A, Ayachi O, Prins F, Durrant LG, Kenter GG, van der Burg SH, Fleuren GJ. Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients? Clin Cancer Res. 2008; 14:2028-2035.
23. Mohos A, Sebestyen T, Liszkay G, Plotar V, Horvath S, Gaudi I, Ladanyi A. Immune cell profile of sentinel lymph nodes in patients with malignant melanoma-FOXP3+ cell density in cases with positive sentinel node status is associated with unfavorable clinical outcome. J Transl Med. 2013; 11:43.
24. Ma MW, Medicherla RC, Qian M, Vega-Saenz de ME, Friedman EB, Berman RS, Shapiro RL, Pavlick AC, Ott PA, Bhardwaj N, Shao Y, Osman I, Darvishian F. Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node. Mod Pathol. 2012; 25:1000-1010.
25. Heusinkveld M, de Vos van Steenwijk PJ, Goedemans R, Ramwadhdoebe TH, Gorter A, Welters MJ, van HT, van der Burg SH. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol. 2011; 187:1157-1165.
26. Gorter A, Zijlmans HJ, van GH, Trimbos JB, Fleuren GJ, Jordanova ES. Versican expression is associated with tumor-infiltrating CD8-positive T cells and infiltration depth in cervical cancer. Mod Pathol. 2010; 23:1605-1615.
27. Rob L, Strnad P, Robova H, Charvat M, Pluta M, Schlegerova D, Hrehorcak M. Study of lymphatic mapping and sentinel node identification in early stage cervical cancer. Gynecol Oncol. 2005; 98:281-288.
28. Marnitz S, Kohler C, Bongardt S, Braig U, Hertel H, Schneider A. Topographic distribution of sentinel lymph nodes in patients with cervical cancer. Gynecol Oncol. 2006; 103:35-44.
29. Cochran AJ, Huang RR, Su A, Itakura E, Wen DR. Is sentinel node susceptibility to metastases related to nodal immune modulation? Cancer J. 2015; 21:39-46.
30. Lentz SE, Muderspach LI, Felix JC, Ye W, Groshen S, Amezcua CA. Identification of micrometastases in histologically negative lymph nodes of early-stage cervical cancer patients. Obstet Gynecol. 2004; 103:1204-1210.
31. Juretzka MM, Jensen KC, Longacre TA, Teng NN, Husain A. Detection of pelvic lymph node micrometastasis in stage IA2-IB2 cervical cancer by immunohistochemical analysis. Gynecol Oncol. 2004; 93:107-111.
32. Kenter GG, Hellebrekers BW, Zwinderman KH, van d V, Peters LA, Trimbos JB. The case for completing the lymphadenectomy when positive lymph nodes are found during radical hysterectomy for cervical carcinoma. Acta Obstet Gynecol Scand. 2000; 79:72-76.